Combined use of ordered mesoporous silica and precipitation inhibitors for improved oral absorption of the poorly soluble weak base itraconazole

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 75, Issue 3, 2010, Pages 354-365

  Van Speybroeck, Michiel ^a   Mols, Raf ^a   Mellaerts, Randy ^b   Thi, Thao Do ^a   Martens, Johan A ^b   Humbeeck, Jan Van ^b   Annaert, Pieter ^a   Mooter, Guy Van den ^a   Augustijns, Patrick ^a  

^a DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Bioavailability; Itraconazole; Mesoporous silica; Precipitation inhibitors; SBA 15; Supersaturation

Indexed keywords

HYDROXYPROPYLMETHYLCELLULOSE; HYDROXYPROPYLMETHYLCELLULOSE ACETATE SUCCINATE; ITRACONAZOLE; NITROGEN; PLURONIC P123; POLOXAMER; SILICON DIOXIDE; UNCLASSIFIED DRUG; WATER;

ADSORPTION; ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG FORMULATION; DRUG SOLUBILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOLECULAR WEIGHT; NONHUMAN; RAT; SYNTHESIS;

ADMINISTRATION, ORAL; ADSORPTION; ANIMALS; ANTIFUNGAL AGENTS; CALORIMETRY, DIFFERENTIAL SCANNING; CHROMATOGRAPHY, LIQUID; ITRACONAZOLE; MALE; MASS SPECTROMETRY; RATS; RATS, WISTAR; SILICON DIOXIDE; SOLUBILITY;

EID: 77954540200     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2010.04.009     Document Type: Article

References (55)

1. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2001, 46:3-26.
2. Lipinski C.A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 2000, 44:235-249.
3. Gribbon P., Sewing A. High-throughput drug discovery: what can we expect from HTS. Drug Discov. Today 2005, 10:17-22.
4. Hancock B.C., Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J. Pharm. Sci. 1997, 86:1-12.
5. Leuner C., Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur. J. Pharm. Biopharm. 2000, 50:47-60.
6. Craig D.Q.M. The mechanisms of drug release from solid dispersions in water-soluble polymers. Int. J. Pharm. 2002, 231:131-144.
7. Serajuddin A.T. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J. Pharm. Sci. 1999, 88:1058-1066.
8. Van Damme H. Nanoscale and mesoscale morphology of silica surfaces. Adsorption on Silica Surfaces 2000, 119-165. Marcel Dekker Inc., New York. E. Papirer (Ed.).
9. Dosseh G., Xia Y., Alba-Simionesco C. Cyclohexane and benzene confined in MCM-41 and SBA-15: confinement effects on freezing and melting. J. Phys. Chem. 2003, 107:6445-6453.
10. Morineau D., Xia Y., Alba-Simionesco C. Finite-size and surface effects on the glass transition of liquid toluene confined in cylindrical mesopores. J. Chem. Phys. 2002, 117:8966-8972.
11. Morishige K., Kawano K. Freezing and melting of methanol in a single cylindrical pore: dynamical supercooling and vitrification of methanol. J. Chem. Phys. 2000, 112:11023.
12. Van Speybroeck M., Barillaro V., Thi T.D., Mellaerts R., Martens J., Van Humbeeck J., Vermant J., Annaert P., Van den Mooter G., Augustijns P. Ordered mesoporous silica material SBA-15: a broad-spectrum formulation platform for poorly soluble drugs. J. Pharm. Sci. 2009, 98:2648-2658.
13. Shen S., Ng W.K., Chia L., Dong Y., Tan R.B.H. Stabilized amorphous state of ibuprofen by co-spray drying with mesoporous SBA-15 to enhance dissolution properties. J. Pharm. Sci. 2009.
14. Mellaerts R., Houthoofd K., Elen K., Chen H., Van Speybroeck M., Van Humbeeck J., Augustijns P., Mullens J., Van den Mooter G., Martens J.A. Aging behavior of pharmaceutical formulations of itraconazole on SBA-15 ordered mesoporous silica carrier material. Micropor. Mesopor. Mater. 2010, 130:154-161.
15. Qu F., Zhu G., Huang S., Li S., Sun J., Zhang D., Qiu S. Controlled release of Captopril by regulating the pore size and morphology of ordered mesoporous silica. Micropor. Mesopor. Mater. 2006, 92:1-9.
16. Mellaerts R., Aerts C.A., Van Humbeeck J., Augustijns P., Van den Mooter G., Martens J.A. Enhanced release of itraconazole from ordered mesoporous SBA-15 silica materials. Chem. Commun. 2007, 1375-1377.
17. Izquierdo-Barba I., Martinez A., Doadrio A.L., Pérez-Pariente J., Vallet-Regí M. Release evaluation of drugs from ordered three-dimensional silica structures. Eur. J. Pharm. Sci. 2005, 26:365-373.
18. Andersson J., Rosenholm J., Areva S., Lindén M. Influences of material characteristics on ibuprofen drug loading and release profiles from ordered micro- and mesoporous silica matrices. Chem. Mater. 2004, 16:4160-4167.
19. Zhao D., Feng J., Huo Q., Melosh N., Fredrickson G., Chmelka B., Stucky G. Triblock copolymer syntheses of mesoporous silica with periodic 50-300 angstrom pores. Science 1998, 279:548-552.
20. Kresge C.T., Leonowicz M.E., Roth W.J., Vartuli J.C., Beck J.S. Ordered mesoporous molecular sieves synthesized by a liquid-crystal template mechanism. Nature 1992, 359:710-712.
21. Inagaki S., Koiwai A., Suzuki N., Fukushima Y., Kuroda K. Syntheses of highly ordered mesoporous materials, FSM-16, derived from Kanemite. Bullet. Chem. Soc. Jpn. 1996, 69:1449-1457.
22. Mellaerts R., Mols R., Jammaer J.A.G., Aerts C.A., Annaert P., Van Humbeeck J., Van den Mooter G., Augustijns P., Martens J.A. Increasing the oral bioavailability of the poorly water soluble drug itraconazole with ordered mesoporous silica. Eur. J. Pharm. Biopharm. 2008, 69:223-230.
23. Brouwers J., Brewster M.E., Augustijns P. Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability. J. Pharm. Sci. 2009, 98:2549-2572.
24. Guzmán H.R., Tawa M., Zhang Z., Ratanabanangkoon P., Shaw P., Gardner C.R., Chen H., Moreau J., Almarsson O., Remenar J.F. Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations. J. Pharm. Sci. 2007, 96:2686-2702.
25. Gao P., Rush B.D., Pfund W.P., Huang T., Bauer J.M., Morozowich W., Kuo M., Hageman M.J. Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability. J. Pharm. Sci. 2003, 92:2386-2398.
26. Gao P., Guyton M.E., Huang T., Bauer J.M., Stefanski K.J., Lu Q. Enhanced oral bioavailability of a poorly water soluble drug PNU-91325 by supersaturatable formulations. Drug Dev. Ind. Pharm. 2004, 30:221-229.
27. Gao P., Akrami A., Alvarez F., Hu J., Li L., Ma C., Surapaneni S. Characterization and optimization of AMG 517 supersaturatable self-emulsifying drug delivery system (S-SEDDS) for improved oral absorption. J. Pharm. Sci. 2009, 98:516-528.
28. Heikkilä T., Salonen J., Tuura J., Kumar N., Salmi T., Murzin D.Y., Hamdy M.S., Mul G., Laitinen L., Kaukonen A.M., Hirvonen J., Lehto V. Evaluation of mesoporous TCPSi, MCM-41, SBA-15, and TUD-1 materials as API carriers for oral drug delivery. Drug Deliv. 2007, 14:337-347.
29. Amidon G.L., Lennernäs H., Shah V.P., Crison J.R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995, 12:413-420.
30. Peeters J., Neeskens P., Tollenaere J.P., Van Remoortere P., Brewster M.E. Characterization of the interaction of 2-hydroxypropyl-beta-cyclodextrin with itraconazole at pH 2, 4, and 7. J. Pharm. Sci. 2002, 91:1414-1422.
31. Prentice A.G., Glasmacher A. Making sense of itraconazole pharmacokinetics. J. Antimicrob. Chemother. 2005, 56(Suppl. 1):i17-i22.
32. Heykants J., Van Peer A., Van de Velde V., Van Rooy P., Meuldermans W., Lavrijsen K., Woestenborghs R., Van Cutsem J., Cauwenbergh G. The clinical pharmacokinetics of itraconazole: an overview. Mycoses 1989, 32(Suppl. 1):67-87.
33. Hardin T.C., Graybill J.R., Fetchick R., Woestenborghs R., Rinaldi M.G., Kuhn J.G. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob. Agents Chemother. 1988, 32:1310-1313.
34. Lange D., Pavao J.H., Wu J., Klausner M. Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers. J. Clin. Pharmacol. 1997, 37:535-540.
35. Jaruratanasirikul S., Kleepkaew A. Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole. Eur. J. Clin. Pharmacol. 1997, 52:235-237.
36. Stein A., Daneshmend T., Warnock D., Bhaskar N., Burke J., Hawkey C. The effects of H2-receptor antagonists on the pharmacokinetics of itraconazole, a new oral antifungal. Br. J. Clin. Pharmacol. 1989, 27:105-106.
37. Galarneau A., Nader M., Guenneau F., DiRenzo F., Gedeon A. Understanding the stability in water of mesoporous SBA-15 and MCM-41. J. Phys. Chem. 2007, 111:8268-8277.
38. Brunauer S., Emmett P.H., Teller E. Adsorption of gases in multimolecular layers. J. Am. Chem. Soc. 1938, 60:309-319.
39. Lippens B.C., De Boer J.H. Studies on pore systems in catalysts. V. The t-method. J. Catal. 1965, 4:319-323.
40. Barrett E.P., Joyner L.G., Halenda P.P. The determination of pore volume and area distribution in porous substances. J. Am. Chem. Soc. 1951, 73:373-380.
41. Janssens S., de Armas H.N., Roberts C.J., Van den Mooter G. Characterization of ternary solid dispersions of itraconazole, PEG 6000, and HPMC 2910 E5. J. Pharm. Sci. 2008, 97:2110-2120.
42. Vertzoni M., Fotaki N., Kostewicz E., Stippler E., Leuner C., Nicolaides E., Dressman J., Reppas C. Dissolution media simulating the intralumenal composition of the small intestine: physiological issues and practical aspects. J. Pharm. Pharmacol. 2004, 56:453-462.
43. Mackie C., Wuyts K., Haseldonckx M., Blokland S., Gysemberg P., Verhoeven I., Timmerman P., Nijsen M. New model for intravenous drug administration and blood sampling in the awake rat, designed to increase quality and throughput for in vivo pharmacokinetic analysis. J. Pharmacol. Toxicol. Methods 2005, 52:293-301.
44. Yoo S.D., Lee S.H., Kang E., Jun H., Jung J.Y., Park J.W., Lee K.H. Bioavailability of itraconazole in rats and rabbits after administration of tablets containing solid dispersion particles. Drug Dev. Ind. Pharm. 2000, 26:27-34.
45. Six K., Verreck G., Peeters J., Binnemans K., Berghmans H., Augustijns P., Kinget R., Van den Mooter G. Investigation of thermal properties of glassy itraconazole: identification of a monotropic mesophase. Thermochim. Acta 2001, 376:175-181.
46. Mellaerts R., Jammaer J.A.G., Van Speybroeck M., Chen H., Van Humbeeck J., Augustijns P., Van den Mooter G., Martens J.A. Physical state of poorly water soluble therapeutic molecules loaded into SBA-15 ordered mesoporous silica carriers: a case study with itraconazole and ibuprofen. Langmuir 2008, 24:8651-8659.
47. Miller D.A., DiNunzio J.C., Yang W., McGinity J.W., Williams R.O.3. Enhanced in vivo absorption of itraconazole via stabilization of supersaturation following acidic-to-neutral pH transition. Drug Dev. Ind. Pharm. 2008, 34:890-902.
48. Dinunzio J.C., Miller D.A., Yang W., McGinity J.W., Williams R.O.3. Amorphous compositions using concentration enhancing polymers for improved bioavailability of itraconazole. Mol. Pharmacol. 2008, 5:968-980.
49. Brewster M.E., Verreck G., Chun I., Rosenblatt J., Mensch J., Van Dijck A., Noppe M., Ariën A., Bruining M., Peeters J. The use of polymer-based electrospun nanofibers containing amorphous drug dispersions for the delivery of poorly water-soluble pharmaceuticals. Pharmazie 2004, 59:387-391.
50. Friesen D.T., Shanker R., Crew M., Smithey D.T., Curatolo W.J., Nightingale J.A.S. Hydroxypropyl methylcellulose acetate succinate-based spray-dried dispersions: an overview. Mol. Pharmacol. 2008, 5:1003-1019.
51. Ziller K.H., Rupprecht H. Control of crystal growth in drug suspensions: 1. Design of a control unit and application to acetaminophen suspensions. Drug Dev. Ind. Pharm. 1988, 14:2341-2370.
52. Raghavan S.L., Trividic A., Davis A.F., Hadgraft J. Crystallization of hydrocortisone acetate: influence of polymers. Int. J. Pharm. 2001, 212:213-221.
53. Mellaerts R., Mols R., Kayaert P., Annaert P., Van Humbeeck J., Van den Mooter G., Martens J.A., Augustijns P. Ordered mesoporous silica induces pH-independent supersaturation of the basic low solubility compound itraconazole resulting in enhanced transepithelial transport. Int. J. Pharm. 2008, 357:169-179.
54. R. Mellaerts, A. Aerts, T.P. Caremans, J. Vermant, G. Van den Mooter, J. A. Martens, P. Augustijns, Growth of itraconazole nanofibers in supersaturated simulated intestinal fluid, Mol. Pharmacol., in press, doi:10.1021/mp900300j.
55. Miller D.A., DiNunzio J.C., Yang W., McGinity J.W., Williams R.O.3. Targeted intestinal delivery of supersaturated itraconazole for improved oral absorption. Pharm. Res. 2008, 25:1450-1459.